A Phase 1/2, Multi-Center, Open-label, Dose-escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.

Trial Profile

A Phase 1/2, Multi-Center, Open-label, Dose-escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 22 Aug 2012

At a glance

  • Drugs Bortezomib; Elotuzumab
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Feb 2012 Planned number of patients changed from 49 to 60 as reported by ClinicalTrials.gov.
    • 27 Feb 2012 Planned End Date changed from 1 Sep 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.
    • 14 Mar 2011 Planned end date changed from 1 Sep 2010 to 1 Sep 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top